---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Cost-effectiveness evidence"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Cost-effectiveness evidence. Topics: Summary: published economic evidence for comparators; U.S. payer cost-effectiveness analysis of elacestrant versus standard endocrine therapy in the second or third line; Drug acquisition costs in the U.S. elacestrant model; Drug cost parameters in the U.S. elacestrant model, US dollars; 24 further topics. 28 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics/cost-effectiveness"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: published economic evidence for comparators

No cost-effectiveness analysis or budget impact model of palazestrant has been published, and no price exists. Published evaluations address the comparators. For elacestrant, a U.S. third-party payer partitioned survival model over 10 years using EMERALD data estimated incremental cost-effectiveness ratios of $8,672,360 per QALY gained compared with standard of care in the overall population and $2,900,560 per QALY gained compared with fulvestrant in the ESR1-mutation subgroup, with a 0% probability of cost-effectiveness at $150,000 per QALY gained. NICE recommends elacestrant for ESR1-mutated disease that progressed after at least 12 months of endocrine treatment plus a CDK4/6 inhibitor, under a commercial arrangement; the committee judged an acceptable ICER to be towards the upper end of £20,000 to £30,000 per QALY gained, the exact estimates are confidential, and the company model assumed £300 per digital polymerase chain reaction ESR1 test and a 50% ESR1-mutation prevalence, or £600 for each case identified for treatment. NICE states that it is “unable to make a recommendation about the use in the NHS of imlunestrant” because the company “does not intend to make an evidence submission for the evaluation”. For capivasertib plus fulvestrant compared with fulvestrant alone, U.S. analyses estimated $128,283.61 per QALY (0.62 incremental QALYs at an incremental cost of $79,117.66; U.S. health care perspective, 10-year horizon, $100,000 per QALY threshold), $280,854 per QALY (lifetime horizon, with a price reduction of nearly 70%, to $7000 per cycle, needed for cost-effectiveness), $636,455 per QALY gained in the PIK3CA/AKT1/PTEN-altered subgroup over 5 years in 2025 U.S. dollars (requiring a reduction from $28,332 to $5,598 per 4 weeks), and $709,647 per QALY in a fourth analysis. The CADTH (Canada) reimbursement review estimated $221,165 per QALY gained compared with endocrine monotherapy, stated that a price reduction of 85% would be required to reach $50,000 per QALY gained, and estimated a 3-year budget impact to public drug plans of $81,103,794, rising to $135,910,918 with 100% testing uptake. A U.S. budget impact analysis of second-line capivasertib in 2023 US dollars estimated 113, 114, and 115 eligible individuals per 1-million-member population in years 1 to 3, $31,939,838 in net costs over 3 years, and $0.88 per member per month. Alpelisib plus fulvestrant had an ICER of $340,153.30 per QALY gained from a U.S. payer perspective. In a 5-year analysis of patient-level data, CDK4/6 inhibitor use in the first line compared with the second line had healthcare costs of €61,821 and €39,057 and an ICER of €423,408 per QALY gained. No Institute for Clinical and Economic Review assessment of therapies for this population was identified.

Source: [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/); [NICE TA1036 recommendation (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/1-Recommendations); [NICE TA1036 committee discussion (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/3-Committee-discussion); [NICE TA1168 terminated appraisal (2026)](https://www.nice.org.uk/guidance/ta1168/chapter/advice); [Okeke et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397977/); [Nguyen and Mital (2025)](https://pubmed.ncbi.nlm.nih.gov/39630382/); [Liang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42009253/); [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11774713/); [CADTH capivasertib reimbursement recommendation (2024)](https://canjhealthtechnol.ca/index.php/cjht/article/download/PC0341/2134?inline=1); [Nguyen and Mital (2026)](https://pubmed.ncbi.nlm.nih.gov/42305034/); [Wu et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37975961/); [Wortelboer et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41207182/)

<a id="topic-4.1-2"></a>

### U.S. payer cost-effectiveness analysis of elacestrant versus standard endocrine therapy in the second or third line

> “The 3 health states partitioned survival model (PSM) was conducted from the perspective of the US third-party payers. The time horizon for the model lasted 10 years. Effectiveness and safety data were derived from the EMERALD trial (NCT03778931).”
> “ELA led to an incremental cost-effectiveness ratio (ICER) of $8,672,360/quality-adjusted life year (QALY) gained compared with SOC in the overall population and $2,900,560/QALY gained compared with fulvestrant (FUL) in the ESR1(estrogen receptor 1) mutation subgroup.”
> “The two ICERs of ELA were significantly higher than the willingness-to-pay (WTP) threshold values of $150,000/QALY.”
> “In both overall population and subgroup, the probability of ELA being cost-effective vs. SOC or FUL at thresholds of $150,000 per QALY gained was 0%.”
> “ELA was not cost-effective for the second-/third-line treatment of patients with ER+/HER2–A/MBC compared with SOC in the US.”

Source: [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/)

<a id="topic-4.1-3"></a>

### Drug acquisition costs in the U.S. elacestrant model

> “As we adopted the perspective of American payers, we only consider direct healthcare costs, including drug acquisition costs, administration and medical fees for each state, end-of-life care costs, and costs associated with MAEs.”
> “The drug unit costs were obtained from the Centers for Medicare & Medicaid Services and AWP&AAC Medicaid, while all other costs were derived from published economic articles on similar drugs, and the cost per cycle was calculated.”
> “the high cost ($22511.06 for 30 tablets, 345mg per tablet)”

Source: [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/)

<a id="topic-4.1-4"></a>

### Drug cost parameters in the U.S. elacestrant model, US dollars

| Variable | Baseline value | Range, first bound | Range, second bound |
| --- | --- | --- | --- |
| “ELA per mg” | “2.175” | “1.088” | “2.610” |
| “FUL per 25mg” | “3.915” | “4.698” | “3.132” |
| “Anastrozole per mg” | “0.107” | “0.086” | “0.128” |
| “Exemestane per 25mg” | “0.713” | “0.571” | “0.855” |
| “Letrozole per 2.5mg” | “0.106” | “0.085” | “0.127” |
| “Subsequent treatment” | “9,061” | “7,248” | “10,873” |
| “Administration” | “702” | “561” | “842” |

Source: [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/)

<a id="topic-4.1-5"></a>

### NICE recommendation for elacestrant in ESR1-mutated disease

> “Elacestrant is recommended as an option for treating oestrogen receptor (ER)-positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation that has progressed after at least 1 line of endocrine treatment plus a cyclin-dependent kinase (CDK) 4 and 6 inhibitor”
> “Elacestrant is recommended only if: the cancer has progressed after at least 12 months of endocrine treatment plus a CDK 4 and 6 inhibitor, and the company provides it according to the commercial arrangement.”

Source: [NICE TA1036 recommendation (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/1-Recommendations)

<a id="topic-4.1-6"></a>

### NICE committee cost-effectiveness estimates and ESR1-mutation testing cost for elacestrant

> “To model ESR1-mutation testing, the company assumed it costs £300 for each digital polymerase chain reaction test using a blood plasma specimen (based on the National Institute for Health and Care Research's interactive costing tool). It also assumed a 50% prevalence of ESR1 mutation (see section 3.1). This gives a cost of £600 for each case identified for treatment.”
> “the committee concluded that an acceptable ICER for both subgroups would be towards the upper end of the range NICE considers a cost-effective use of NHS resources (£20,000 to £30,000 per QALY gained).”
> “The committee considered the cost effectiveness of elacestrant in the activating ESR1-mutation subgroup compared with everolimus plus exemestane and in the dual-mutated subset compared with alpelisib plus fulvestrant. In both the company's and EAG's revised base cases, the deterministic and probabilistic ICERs were within the range the committee considered to be acceptable for this evaluation (see section 3.18). The exact cost-effectiveness estimates cannot be reported because of confidential price discounts.”

Source: [NICE TA1036 committee discussion (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/3-Committee-discussion)

<a id="topic-4.1-7"></a>

### NICE terminated appraisal of imlunestrant

> “NICE is unable to make a recommendation about the use in the NHS of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy in adults. The company has confirmed that it does not intend to make an evidence submission for the evaluation. This is because the technology is unlikely to be a cost-effective use of NHS resources.”

Source: [NICE TA1168 terminated appraisal (2026)](https://www.nice.org.uk/guidance/ta1168/chapter/advice)

<a id="topic-4.1-8"></a>

### CADTH reimbursement recommendation for capivasertib plus fulvestrant: cost-effectiveness

> “Using the sponsor-submitted price for capivasertib and publicly listed prices for all other drug costs, the incremental cost-effectiveness ratio (ICER) for capivasertib plus fulvestrant was $221,165 per quality-adjusted life-year (QALY) gained, compared with endocrine monotherapy in adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.”
> “A price reduction of 85% would be required for capivasertib to achieve an ICER of $50,000 per QALY gained when compared to endocrine monotherapy.”
> “Cost-effectiveness vs. chemotherapy and everolimus plus exemestane could not be established due to uncertainties with the indirect evidence.”

Source: [CADTH capivasertib reimbursement recommendation (2024)](https://canjhealthtechnol.ca/index.php/cjht/article/download/PC0341/2134?inline=1)

<a id="topic-4.1-9"></a>

### CADTH reimbursement recommendation for capivasertib plus fulvestrant: budget impact

> “Based on the public list price, Truqap is estimated to cost the public drug plans approximately $81 million over the next 3 years. The testing uptake is 1 of the main factors that impacts the size of the budget impact analysis (BIA).”
> “would be associated with a 3-year budget impact of $81,103,794 (year 1: $16,102,743; year 2: $26,971,824; year 3: $38,029,227).”
> “If testing uptake reached 100%, then the budget impact would increase to $135,910,918.”

Source: [CADTH capivasertib reimbursement recommendation (2024)](https://canjhealthtechnol.ca/index.php/cjht/article/download/PC0341/2134?inline=1)

<a id="topic-4.1-10"></a>

### U.S. health care perspective cost-effectiveness analysis of capivasertib plus fulvestrant (CAPItello-291 overall population)

> “This model adopted a willingness-to-pay (WTP) threshold of $100,000 per quality-adjusted life-year (QALY) from a US health care perspective. A 10-year lifetime horizon with a monthly cycle length was used with a 3% discount on costs and utilities derived from previously published resources.”
> “In the base model, capivasertib plus fulvestrant treatment was expected to generate an incremental 0.62 QALYs at an incremental cost of $79,117.66, which resulted in an incremental cost-effectiveness ratios of $128,283.61/QALY.”
> “The findings from this study suggest that adding capivasertib to fulvestrant treatment is not cost-effective when compared with fulvestrant alone, from the perspective of the US health care system.”
> “The drug costs per unit were calculated using the 2023 average sale price data provided by the Centers for Medicare & Medicaid Services.”

Source: [Okeke et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397977/)

<a id="topic-4.1-11"></a>

### U.S. payer cost-effectiveness analysis of capivasertib plus fulvestrant (partitioned survival model)

> “The base-case analysis estimated the ICUR for capivasertib plus fulvestrant versus fulvestrant alone to be $709,647 per quality-adjusted life-year (QALY) in the US.”
> “OWSA revealed that the results were sensitive to hazard ratio of OS and the cost of capivasertib. PSA demonstrated that capivasertib plus fulvestrant exhibited a 0% probability of cost-effectiveness in the US.”

Source: [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11774713/)

<a id="topic-4.1-12"></a>

### U.S. payer cost-effectiveness analysis of capivasertib plus fulvestrant (lifetime horizon)

> “Analyses were conducted from a US payer perspective over a lifetime horizon.”
> “The addition of capivasertib to fulvestrant for all patients was associated with $410,765 higher costs and 1.46 additional quality adjusted life years (QALYs) compared with fulvestrant alone, resulting in an incremental cost effectiveness ratio of $280,854/QALY.”
> “The price of capivasertib will need to be reduced by nearly 70% (to $7000 per cycle) for it to become cost effective.”

Source: [Nguyen and Mital (2025)](https://pubmed.ncbi.nlm.nih.gov/39630382/)

<a id="topic-4.1-13"></a>

### U.S. payer cost-effectiveness analysis of capivasertib plus fulvestrant (PIK3CA/AKT1/PTEN-altered subgroup)

> “Capivasertib cost was based on wholesale acquisition cost. Costs were presented in 2025 U.S. dollars.”
> “Capivasertib plus fulvestrant yielded more QALYs (1.89 vs. 1.29) and life years (3.31 vs. 2.49) but higher costs ($539,625 vs. $158,679) than fulvestrant alone, resulting in ICERs of $636,455/QALY gained and $459,358/evLYG over a 5-year time horizon.”
> “The cost of capivasertib ($28,332/4 weeks) had the greatest impact and would need to be reduced to $5,598/4 weeks to achieve cost-effectiveness.”

Source: [Liang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42009253/)

<a id="topic-4.1-14"></a>

### U.S. payer cost-effectiveness analysis of alpelisib plus fulvestrant (PIK3CA-mutated disease)

> “The QALY increased by 0.28 with alpelisib plus fulvestrant with an additional cost of $94,345.87 compared with placebo plus fulvestrant, leading to an incremental cost-effectiveness ratio (ICER) of $340,153.30/QALY gained.”
> “At current drug prices, alpelisib plus fulvestrant is not cost effective for patients with PIK3CA-mutated, HR+/HER2- ABC from a US payer perspective.”

Source: [Wu et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37975961/)

<a id="topic-4.1-15"></a>

### Cost-effectiveness of CDK4/6 inhibitor use in first versus second line (SONIA)

> “We estimated the cost-effectiveness of CDK4/6i use in first- versus second-line over 5 years using patient-level data.”
> “Healthcare costs were higher among patients receiving CDK4/6i in first- versus second-line (€61,821 [SE 1423] versus €39,057 [SE 1513]; difference €22,764, 95 % CI €18,815 to €26,713).”
> “The ICER was €423,408 per QALY gained.”
> “Delaying CDK4/6i treatment to second-line leads to large cost savings while achieving the same patient health outcomes.”

Source: [Wortelboer et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41207182/)

<a id="topic-4.1-16"></a>

### U.S. budget impact analysis of capivasertib as second-line therapy

> “We estimated the change in total costs from adding capivasertib to the treatment mix over 3 years. The size of the target population was estimated using data on incidence and prevalence for breast cancer, PIK3CA/AKT1/PTEN alterations, and risk of failure to first-line treatment.”
> “Costs were measured in 2023 US dollars.”
> “In a 1-million-member population, 113, 114, and 115 individuals would be eligible for capivasertib treatment in years 1, 2, and 3, respectively. Adding capivasertib to the second-line setting would add $31,939,838 in net costs over 3 years.”
> “Specifically, drug costs would increase by $34,251,781 but would be offset by savings of $323,632 in adverse event costs and of $1,988,311 in follow-up costs. These net costs amount to $0.88 per-member-per-month.”

Source: [Nguyen and Mital (2026)](https://pubmed.ncbi.nlm.nih.gov/42305034/)

<a id="topic-4.1-17"></a>

### ICER review of therapies for ER-positive HER2-negative advanced breast cancer

No evidence found.

<a id="topic-4.1-18"></a>

### Eligible population input: incident invasive breast cancer in the United States, 2026

> “About 321,910 new cases of invasive breast cancer will be diagnosed in women.”

Source: [American Cancer Society Key Statistics for Breast Cancer (2026)](https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html)

<a id="topic-4.1-19"></a>

### Eligible population input: stage distribution at diagnosis and prevalence of female breast cancer

| Stage | Percent of cases | 5-year relative survival |
| --- | --- | --- |
| “Localized” | “64%” | “100.0%” |
| “Regional” | “27%” | “87.5%” |
| “Distant” | “6%” | “33.8%” |
| “Unknown” | “2%” | “70.6%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

> “In 2023, there were an estimated 4,238,585 women living with female breast cancer in the United States.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-4.1-20"></a>

### Eligible population input: share of female breast cancer that is HR-positive HER2-negative

> “The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 92.9 new cases per 100,000 women, based on 2019–2023 cases.”
> “HR+/HER2- (70%)”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-4.1-21"></a>

### Eligible population input: number of women living with metastatic breast cancer in the United States

> “By January 1, 2025, the following numbers of individuals are projected to be living with metastatic cancer in the United States: breast, 169 347”

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

| Cancer type | New metastatic cases, 2018, de novo (observed) | New metastatic cases, 2018, de novo and recurrence (estimated) | Living with metastatic disease on January 1, 2018, de novo (observed) | Living with metastatic disease on January 1, 2018, de novo and recurrence (estimated) |
| --- | --- | --- | --- | --- |
| “Breast (female)” | “15 800” | “46 666” | “54 117” | “140 230” |

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

<a id="topic-4.1-22"></a>

### Eligible population input: second-line treatment after first-line CDK4/6 inhibitor therapy in U.S. practice

> “A total of 1210 patients with MBC received a CDK4/6i with ET as their documented first-line systemic therapy from years 2015-2020”
> “Eight hundred thirty-nine patients received a documented second-line systemic therapy”
> “Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively. Fulvestrant was the most commonly prescribed endocrine monotherapy (70 patients, 8.3%). Other targeted therapies used were everolimus (99 patients, 11.7%), alpelisib (16 patients, 1.9%) and a PARP inhibitor (4 patients, 0.5%).”
> “Three hundred two (36.0%) of patients continued a CDK4/6i.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-4.1-23"></a>

### Treatment duration input: real-world progression-free survival of second-line regimens after first-line CDK4/6 inhibitor therapy

> “Twenty records (9 full-text articles and 11 conference abstracts) encompassing 18 unique studies met the eligibility criteria and reported outcomes for second-line (2 L) treatments after 1 L CDK4/6i; no studies reported disaggregated outcomes in the third-line setting or beyond.”
> “the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-4.1-24"></a>

### Eligible population input: ESR1-mutation prevalence by line of therapy

> “Evaluating specimens collected at or near the time of therapy initiation, the prevalence of ESR1mut in TBx collected within 60 days before or after the initiation of 1st, 2nd, and 3rd lines of therapy was 8.1% (n = 175/2,154), 27.1% (n = 73/269), and 33.3% (n = 72/216), respectively.”
> “The prevalence of ESR1mut in LBx collected proximal to initiation of 1st, 2nd, and 3rd lines of therapy was 10.4% (n = 30/288), 37.6% (n = 74/197), and 38.7% (n = 46/119), respectively”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-4.1-25"></a>

### Company market-size statements in the annual report

> “Approximately 79% of all breast cancers are ER+, and approximately 70% are ER+/HER2-, highlighting the central role of the ER in driving a large majority of breast cancer. Approximately 6-10% of breast cancer patients present with metastatic disease at diagnosis and a further 20-30% of patients initially diagnosed with early-stage disease ultimately develop metastatic disease.”
> “Based on our internal estimates, we believe that the current global ER+/HER2- metastatic breast cancer market represents approximately $20 billion. In the U.S. and E.U., we believe the market potential for palazestrant is up to $5 billion in the second- and third-line settings and up to $10 billion in the first-line setting.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-4.1-26"></a>

### Company estimate of the U.S. second- and third-line population and market

> “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”
> “Annual U.S. incidence estimated at ~40K”
> “U.S. market potential of ~$3-5B”
> “Olema internal estimate of US market.”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-4.1-27"></a>

### Comparator price: imlunestrant wholesale acquisition cost

| Generic name | Strength | Dosage form | Pack size | NDC | Wholesale acquisition cost |
| --- | --- | --- | --- | --- | --- |
| “imlunestrant” | “200 MG” | “Tablet” | “28” | “0002-1717-28” | “$11,250.00” |
| “imlunestrant” | “200 MG” | “Tablet” | “56” | “0002-1717-56” | “$22,500.00” |

Source: [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf)

<a id="topic-4.1-28"></a>

### Comparator price: elacestrant wholesale acquisition cost at launch

| Name of prescription drug | Strength | Pack size | WAC (as of date of commercial availability) | Date of commercial availability |
| --- | --- | --- | --- | --- |
| “Orserdu (elacestrant)” | “86 mg” | “30 tablets” | “$7,123.00” | “2/3/2023” |
| “Orserdu (elacestrant)” | “345 mg” | “30 tablets” | “$21,369.00” | “2/3/2023” |

Source: [Vermont Attorney General Orserdu report (2023)](https://ago.vermont.gov/sites/ago/files/2023-11/VT-high-cost-prescription-drug-reporting%20Orserdu.pdf)

<a id="topic-4.1-29"></a>

### Comparator price: fulvestrant cost per cycle in a U.S. model based on CMS average sales price

| Parameter | Value | Range |
| --- | --- | --- |
| “Fulvestrant per cycle” | “1,129.2” | “(903.36-1,355.04)” |

Source: [Okeke et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397977/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
